Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arvinas Inc ARVN

Healthcare
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein... see more

Recent & Breaking News (NDAQ:ARVN)

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

PR Newswire May 9, 2022

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 5, 2022

Arvinas to Present at Bank of America Securities 2022 Healthcare Conference

GlobeNewswire May 3, 2022

Arvinas to Present at Upcoming Investor Conferences

GlobeNewswire March 4, 2022

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire February 28, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire February 17, 2022

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

GlobeNewswire February 14, 2022

Arvinas to Present at Upcoming Investor Conferences

GlobeNewswire February 3, 2022

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

GlobeNewswire December 10, 2021

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

GlobeNewswire November 19, 2021

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 10, 2021

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 3, 2021

Arvinas to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire September 1, 2021

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

PR Newswire August 9, 2021

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2021

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

GlobeNewswire July 22, 2021

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

GlobeNewswire June 7, 2021

Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire June 3, 2021

Arvinas to Present at the UBS Global Healthcare Virtual Conference

GlobeNewswire May 20, 2021

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

GlobeNewswire May 4, 2021